The Latest Breaking News from Wedbush

Apellis Pharmaceuticals’ (APLS) stock has jumped more than 25% year-to-date based on FDA approval for treating geographic atrophy. Despite the breakthrough, the company’s ability to scale up production remains a concern. Moreover, its closest competitor is also close to getting approval. Given its poor financials, stretched valuation, and weak profitability,…

Tech companies are racing to figure out how to implement A.I. in their products, and it’s not just about search engines.

“There is a window of opportunity to gain share...and 2023 is a pivotal year that will establish the winners and losers in this EV landscape,” Wedbush tech analyst Dan Ives says amid the industry's price cuts.

Dow Jones rose as the Nasdaq added to its three-week win streak. Wedbush analysts sees 35% upside to Tesla; Microsoft, Salesforce, Tesla on deck.

Microsoft is readying to cut more positions from its global workforce as tech giants continue paring headcount to ride out rough economic conditions, according to media reports on Tuesday. The computer industry stalwart could announce layoffs in its engineering divisions as early as Wednesday, Bloomberg News reported. A Microsoft spokesperson…

Wedbush analyst Dan Ives argued that lowering prices was the correct strategic move for Tesla, while Guggenheim Securities said it sacrifices gross margins.

Microsoft's proposed investment in OpenAI is a "smart poker move" as A.I. advances, Wedbush's top tech analyst argues.

“The Cinderella ride is over for Tesla, and Musk now needs to navigate the company through this Category 5 dark macro storm,” Tesla bull Dan Ives wrote in a Tuesday note.

Wedbush’s Dan Ives is celebrating the likely end of Elon Musk’s reign as Twitter CEO, arguing it was a “nightmare” for Tesla investors.